NCT05570253 2026-04-17
A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
Clinical Trials
10 trialsNCT03237780 2026-04-13
Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT07007559 2026-04-13
ASPEN-09-03
ALX Oncology Inc.
Phase 2 Recruiting
NCT07520760 2026-04-09
MBC-EA
Sun Yat-sen University
Phase 2 Recruiting
NCT05458674 2026-04-03
Tucatinib+Trastuzumab+Eribulin in HER2+ MBC
Criterium, Inc.
Phase 2 Recruiting
NCT07203729 2026-03-16
The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06875128 2026-03-13
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease
Delcath Systems Inc.
Phase 2 Recruiting
NCT05810870 2026-03-10
SABINA
MedSIR
Phase 2 Active not recruiting
NCT07441512 2026-03-02
A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation
Zhejiang Cancer Hospital
Phase 2 Not yet recruiting
NCT06449222 2026-02-25
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
BioNTech SE
Phase 2 Active not recruiting